- Home
- ACB vs RVNC Comparison
ACB vs RVNC Comparison
Compare ACB & RVNC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACB
- RVNC
- Stock Information
- Founded
- ACB 2013
- RVNC 1999
- Country
- ACB Canada
- RVNC United States
- Employees
- ACB N/A
- RVNC N/A
- Industry
- ACB Pharmaceuticals and Biotechnology
- RVNC Biotechnology: Pharmaceutical Preparations
- Sector
- ACB Health Care
- RVNC Health Care
- Exchange
- ACB Nasdaq
- RVNC Nasdaq
- Market Cap
- ACB 315.4M
- RVNC 546.4M
- IPO Year
- ACB N/A
- RVNC 2014
- Fundamental
- Price
- ACB $5.51
- RVNC $5.28
- Analyst Decision
- ACB Hold
- RVNC Buy
- Analyst Count
- ACB 1
- RVNC 10
- Target Price
- ACB N/A
- RVNC $10.86
- AVG Volume (30 Days)
- ACB 659.5K
- RVNC 1.8M
- Earning Date
- ACB 11-07-2024
- RVNC 11-06-2024
- Dividend Yield
- ACB N/A
- RVNC N/A
- EPS Growth
- ACB N/A
- RVNC N/A
- EPS
- ACB N/A
- RVNC N/A
- Revenue
- ACB $203,838,819.00
- RVNC $251,178,000.00
- Revenue This Year
- ACB $14.04
- RVNC $20.36
- Revenue Next Year
- ACB $8.94
- RVNC $31.66
- P/E Ratio
- ACB N/A
- RVNC N/A
- Revenue Growth
- ACB 12.30
- RVNC 40.23
- 52 Week Low
- ACB $2.84
- RVNC $2.30
- 52 Week High
- ACB $9.35
- RVNC $9.75
- Technical
- Relative Strength Index (RSI)
- ACB 46.80
- RVNC 43.99
- Support Level
- ACB $5.46
- RVNC $5.10
- Resistance Level
- ACB $5.66
- RVNC $5.43
- Average True Range (ATR)
- ACB 0.17
- RVNC 0.17
- MACD
- ACB 0.03
- RVNC 0.02
- Stochastic Oscillator
- ACB 71.15
- RVNC 64.29
About ACB Aurora Cannabis Inc.
Aurora Cannabis, headquartered in Edmonton, Canada, cultivates and sells medicinal and recreational cannabis through a portfolio of brands that includes Drift, San Rafael '71, Daily Special, Whistler, Being, and Greybeard. Although the company primarily operates in Canada, it has expanded internationally through medical cannabis exporting agreements.
About RVNC Revance Therapeutics Inc.
Revance Therapeutics Inc is a biotechnology company focused on aesthetic and therapeutic offerings, including its neuromodulator product, DaxibotulinumtoxinA for Injection. The company has launched a prestige aesthetics portfolio, which includes the RHA Collection of dermal fillers and the HintMD platform. Its main products include DaxibotulinumtoxinA for Injection and DaxibotulinumtoxinA for Injection Aesthetics. The operating business segments are the Product and the Service Segment. The Products segment generates maximum revenue and is engaged in the research and development of aesthetic and therapeutic products.